Clinical trials: CD7+ T-ALL/LBL, open to volunteers
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
T Lymphoblastic Leukemia/Lymphoma
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
- Trial name
- NCT07244380
- Testing
- Autologous CD7-targeting CAR T cells
- Volunteers
- 38 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
CD7+ T-ALL/LBL
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic…
- Trial name
- R/R T-ALL/LBL (NCT07623681)
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 12 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD…
- Trial name
- NCT05626400
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.
- Trial name
- NCT07153068
- Testing
- supCD7 CART cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T-lymphoblastic Lymphoma, T-ALL
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
- Trial name
- NCT06136364
- Testing
- CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia
Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
This study is an open, single-center, prospective clinical trial, with newly diagnosed high-risk T-LBL/ALL patients as the subjects. It plans to enroll 10 subjects.
- Trial name
- NCT07476027
- Testing
- CD7 CAR-T cell intravenous infusion
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.
- Trial name
- NCT07109518
- Testing
- uCD7 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial.
- Trial name
- NCT05509855
- Testing
- Genetic: WU-CART-007
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Allotera Therapeutics